Hannah joined Charles River in July 2004 progressing from Analyst to Study Director. She and her team support in vitro, pre-clinical, and clinical bioanalytical validations and routine studies using HPLC with mass spectrometry detection.
eGuide: Bioanalysis from Early-Stage to Clinical Drug Development
Accounting for modality complexity, evolving regulatory expectations, and the critical importance of upfront planning, this eGuide addresses how to identify risks early and align your bioanalytical strategy with the needs of your compound, your timeline, and your team.
Learn More